Cetera Advisor Networks LLC Profound Medical Corp. Transaction History

Cetera Advisor Networks LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$7.3 - $9.46 $365 - $473	-50 Reduced 0.43%	11,619 $99,000
Q2 2023 Aug 09, 2023	SELL	$9.27 - $14.88 $2,641 - $4,240	-285 Reduced 2.38%	11,669 $151,000
Q1 2023 May 15, 2023	BUY	$8.85 - $13.27 $4,734 - $7,099	535 Added 4.69%	11,954 $111,000
Q4 2022 Feb 14, 2023	BUY	$3.18 - $10.91 $3,180 - $10,910	1,000 Added 9.6%	11,419 $124,000
Q3 2022 Nov 10, 2022	SELL	$3.99 - $9.3 $399 - $930	-100 Reduced 0.95%	10,419 $42,000
Q2 2022 Aug 11, 2022	BUY	$6.34 - $9.53 $66,690 - $100,246	10,519 New	10,519 $77,000
Q3 2020 Nov 13, 2020	SELL	$14.05 - $18.13 $112,400 - $145,040	-8,000 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$9.41 - $16.94 $75,280 - $135,520	8,000 New	8,000 $135,000

8.93M

1.2K

Ticker PROF
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,851,300
Market Cap $157M
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.